Stephanie Philbin, a counsel in the firm’s FDA Group and a member of its Life Sciences Practice, concentrates on Food and Drug Administration laws. She joined Goodwin Procter in 2007.

Ms. Philbin advises clients on regulatory and compliance issues including those related to clinical trials, pre-market submissions, the Quality System Regulation, Medical Device Reporting, recalls, product importing and exporting, and product promotion. Ms. Philbin assists clients in responding to agency investigations and in filing comments with FDA to respond to various regulatory initiatives. She reviews SEC filings of FDA-regulated companies and conducts due diligence of companies as part of mergers and acquisitions and initial public offerings. Ms. Philbin also assists in litigation.